Alpha-Lipoic Acid: A Treatment Option for Diabetic Patients with COVID-19
,
Abstract
The new coronavirus pneumonia, which first occurred in China in December 2019, has a wide spectrum of symptoms from asymptomatic to very severe involvement and even death. The main reason for the increase in the severity of this disease is the body's inflammatory response to the virus, and due to the lack of effective antiviral treatment for this disease, it is necessary to take therapeutic interventions to reduce the body's inflammatory response. It is noteworthy that diabetic patients are more severely exposed to this disease and this calls for appropriate treatment to control diabetes in patients with COVID19. In addition to its antioxidant and anti-inflammatory effects, alpha lipoic acid also has therapeutic effects in controlling diabetes and blood sugar. Therefore, it is suggested that clinical trials be performed to evaluate the effects of alpha-lipoic acid on diabetic patients with COVID19
1. Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus out break of global health concern. Lancet. 2020;395(10223):470-3. doi:10.1016/S0140-6736(20)30185-9. [PubMed:31986257].
2. Gorbalenya AE, Baker SC, Baric RS, de Groot RJ, Drosten C, Guly aeva AA, et al. Severe acute respiratory syndrome-related corona virus: The species and its viruses – a statement of the Coronavirus study group. BioRxiv. 2020. doi:10.1101/2020.02.07.937862.
3. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneu monia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270-3. doi:10.1038/s41586-020- 2012-7. [PubMed:32015507].
4. Linton NM, Kobayashi T, Yang Y, Hayashi K, Akhmetzhanov AR, Jung SM, et al. Incubation period and other epidemiological char acteristics of 2019 novel coronavirus infections with right trun cation: A statistical analysis of publicly available case data. J Clin Med. 2020;9(2). doi:10.3390/jcm9020538. [PubMed:32079150].
5. Yang W, Cao Q , Qin L, Wang X, Cheng Z, Pan A, et al. Clinical char acteristics and imaging manifestations of the 2019 novel coro navirus disease (COVID-19):A multi-center study in Wenzhou city, Zhejiang, China. J Infect. 2020;80(4):388-93. doi:10.1016/j. jinf.2020.02.016. [PubMed:32112884].
6. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q , et al. Neurologic mani festations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020;77(6):683-90. doi:10.1001/ja maneurol.2020.1127. [PubMed:32275288].
7. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemio logical and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-13. doi:10.1016/S0140-6736(20)30211- 7. [PubMed:32007143].
8. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: consider cytokine storm syndromes and im munosuppression. Lancet. 2020;395(10229):1033-4. doi:10.1016/ S0140-6736(20)30628-0. [PubMed:32192578].
9. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. doi:10.1016/s0140- 6736(20)30183-5. 10. Liu J, Li S, Liu J, Liang B, Wang X, Wang H, et al. Longitudinal characteristics of lymphocyte responses and cytokine pro files in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine. 2020;55:102763. doi:10.1016/j.ebiom.2020.102763. [PubMed:32361250].
11. Li X, Wang L, Yan S, Yang F, Xiang L, Zhu J, et al. Clinical charac teristics of 25 death cases with COVID-19: A retrospective review of medical records in a single medical center, Wuhan, China. Int J Infect Dis. 2020;94:128-32. doi:10.1016/j.ijid.2020.03.053. [PubMed:32251805].
12. Thomas RL, Halim S, Gurudas S, Sivaprasad S, Owens DR. IDF Diabetes Atlas: A review of studies utilising retinal photogra phy on the global prevalence of diabetes related retinopathy between 2015 and 2018. Diabetes Res Clin Pract. 2019;157:107840. doi:10.1016/j.diabres.2019.107840. [PubMed:31733978].
13. Hussain A, Bhowmik B, do Vale Moreira NC. COVID-19 and diabetes: Knowledge in progress. Diabetes Res Clin Pract. 2020;162:108142. doi:10.1016/j.diabres.2020.108142. [PubMed:32278764].
14. Zhang Y, Cui Y, Shen M, Zhang J, Liu B, Dai M, et al. Comorbid dia betes mellitus was associated with poorer prognosis in patients with COVID-19: A retrospective cohort study. medRxiv 2020. doi:1 0.1101/2020.03.24.20042358.
15. Pavoni V, Gianesello L. COVID-19 infection: Is the outcome time dependent? Med Hypotheses. 2020;144:109902. doi:10.1016/j. mehy.2020.109902. [PubMed:32505068].
16. El Barky A, Hussein S, Mohamed T. The potent antioxidant alpha lipoic acid. J Plant Chem Ecophysiol. 2017;2(1):1016.
17. Biewenga GP, Haenen GR, Bast A. The pharmacology of the anti oxidant lipoic acid. Gen Pharmacol. 1997;29(3):315-31. doi:10.1016/ s0306-3623(96)00474-0. [PubMed:9378235].
18. Haghighatdoost F, Hariri M. The effect of alpha-lipoic acid on inflammatory mediators: a systematic review and meta-analysis on randomized clinical trials. Eur J Pharmacol. 2019;849:115-23. doi:10.1016/j.ejphar.2019.01.065. [PubMed:30721699].
19. Bramanti V, Tomassoni D, Bronzi D, Grasso S, Curro M, Avitabile M, et al. Alpha-lipoic acid modulates GFAP, vimentin, nestin, cyclin D1 and MAP-kinase expression in astroglial cell cultures. Neurochem Res. 2010;35(12):2070-7. doi:10.1007/s11064-010-0256-6. [PubMed:20814740].
20. Zhao L, Hu FX. alpha-Lipoic acid treatment of aged type 2 diabe tes mellitus complicated with acute cerebral infarction. Eur Rev Med Pharmacol Sci. 2014;18(23):3715-9. [PubMed:25535146].
21. Eason RC, Archer HE, Akhtar S, Bailey CJ. Lipoic acid increases glucose uptake by skeletal muscles of obese-diabetic ob/ob mice. Diabetes Obes Metab. 2002;4(1):29-35. doi:10.1046/j.1463- 1326.2002.00171.x. [PubMed:11874439].
22. Zhong M, Sun A, Xiao T, Yao G, Sang L, Zheng X, et al. A random ized, single-blind, group sequential, active-controlled study to evaluate the clinical efficacy and safety of α-Lipoic acid for criti cally ill patients with coronavirus disease 2019 (COVID-19). Me dRxiv. 2020
2. Gorbalenya AE, Baker SC, Baric RS, de Groot RJ, Drosten C, Guly aeva AA, et al. Severe acute respiratory syndrome-related corona virus: The species and its viruses – a statement of the Coronavirus study group. BioRxiv. 2020. doi:10.1101/2020.02.07.937862.
3. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneu monia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270-3. doi:10.1038/s41586-020- 2012-7. [PubMed:32015507].
4. Linton NM, Kobayashi T, Yang Y, Hayashi K, Akhmetzhanov AR, Jung SM, et al. Incubation period and other epidemiological char acteristics of 2019 novel coronavirus infections with right trun cation: A statistical analysis of publicly available case data. J Clin Med. 2020;9(2). doi:10.3390/jcm9020538. [PubMed:32079150].
5. Yang W, Cao Q , Qin L, Wang X, Cheng Z, Pan A, et al. Clinical char acteristics and imaging manifestations of the 2019 novel coro navirus disease (COVID-19):A multi-center study in Wenzhou city, Zhejiang, China. J Infect. 2020;80(4):388-93. doi:10.1016/j. jinf.2020.02.016. [PubMed:32112884].
6. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q , et al. Neurologic mani festations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020;77(6):683-90. doi:10.1001/ja maneurol.2020.1127. [PubMed:32275288].
7. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemio logical and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-13. doi:10.1016/S0140-6736(20)30211- 7. [PubMed:32007143].
8. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: consider cytokine storm syndromes and im munosuppression. Lancet. 2020;395(10229):1033-4. doi:10.1016/ S0140-6736(20)30628-0. [PubMed:32192578].
9. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. doi:10.1016/s0140- 6736(20)30183-5. 10. Liu J, Li S, Liu J, Liang B, Wang X, Wang H, et al. Longitudinal characteristics of lymphocyte responses and cytokine pro files in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine. 2020;55:102763. doi:10.1016/j.ebiom.2020.102763. [PubMed:32361250].
11. Li X, Wang L, Yan S, Yang F, Xiang L, Zhu J, et al. Clinical charac teristics of 25 death cases with COVID-19: A retrospective review of medical records in a single medical center, Wuhan, China. Int J Infect Dis. 2020;94:128-32. doi:10.1016/j.ijid.2020.03.053. [PubMed:32251805].
12. Thomas RL, Halim S, Gurudas S, Sivaprasad S, Owens DR. IDF Diabetes Atlas: A review of studies utilising retinal photogra phy on the global prevalence of diabetes related retinopathy between 2015 and 2018. Diabetes Res Clin Pract. 2019;157:107840. doi:10.1016/j.diabres.2019.107840. [PubMed:31733978].
13. Hussain A, Bhowmik B, do Vale Moreira NC. COVID-19 and diabetes: Knowledge in progress. Diabetes Res Clin Pract. 2020;162:108142. doi:10.1016/j.diabres.2020.108142. [PubMed:32278764].
14. Zhang Y, Cui Y, Shen M, Zhang J, Liu B, Dai M, et al. Comorbid dia betes mellitus was associated with poorer prognosis in patients with COVID-19: A retrospective cohort study. medRxiv 2020. doi:1 0.1101/2020.03.24.20042358.
15. Pavoni V, Gianesello L. COVID-19 infection: Is the outcome time dependent? Med Hypotheses. 2020;144:109902. doi:10.1016/j. mehy.2020.109902. [PubMed:32505068].
16. El Barky A, Hussein S, Mohamed T. The potent antioxidant alpha lipoic acid. J Plant Chem Ecophysiol. 2017;2(1):1016.
17. Biewenga GP, Haenen GR, Bast A. The pharmacology of the anti oxidant lipoic acid. Gen Pharmacol. 1997;29(3):315-31. doi:10.1016/ s0306-3623(96)00474-0. [PubMed:9378235].
18. Haghighatdoost F, Hariri M. The effect of alpha-lipoic acid on inflammatory mediators: a systematic review and meta-analysis on randomized clinical trials. Eur J Pharmacol. 2019;849:115-23. doi:10.1016/j.ejphar.2019.01.065. [PubMed:30721699].
19. Bramanti V, Tomassoni D, Bronzi D, Grasso S, Curro M, Avitabile M, et al. Alpha-lipoic acid modulates GFAP, vimentin, nestin, cyclin D1 and MAP-kinase expression in astroglial cell cultures. Neurochem Res. 2010;35(12):2070-7. doi:10.1007/s11064-010-0256-6. [PubMed:20814740].
20. Zhao L, Hu FX. alpha-Lipoic acid treatment of aged type 2 diabe tes mellitus complicated with acute cerebral infarction. Eur Rev Med Pharmacol Sci. 2014;18(23):3715-9. [PubMed:25535146].
21. Eason RC, Archer HE, Akhtar S, Bailey CJ. Lipoic acid increases glucose uptake by skeletal muscles of obese-diabetic ob/ob mice. Diabetes Obes Metab. 2002;4(1):29-35. doi:10.1046/j.1463- 1326.2002.00171.x. [PubMed:11874439].
22. Zhong M, Sun A, Xiao T, Yao G, Sang L, Zheng X, et al. A random ized, single-blind, group sequential, active-controlled study to evaluate the clinical efficacy and safety of α-Lipoic acid for criti cally ill patients with coronavirus disease 2019 (COVID-19). Me dRxiv. 2020
| Files | ||
| Issue | Vol 4, No 3 (2020) | |
| Section | Letter | |
| DOI | https://doi.org/10.18502/htaa.v4i3.6352 | |
| Keywords | ||
| Alpha lipoic acid treatment diabetic patients Covid 19 | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Moghadam H, Maniati M. Alpha-Lipoic Acid: A Treatment Option for Diabetic Patients with COVID-19. Health Tech Ass Act. 2021;4(3).
